Press release

Medicines Development retains the services of d3 Medicine

November 25, 2015

Medicines Development for Global Health has retained the services of d3 Medicine to provide strategic advice on the regulatory strategy to support the registration of moxidectin for onchocerciasis.

The services of d3 Medicine have been retained through an innovative risk-share agreement for the benefit of both companies.

Medicines Development for Global Health has retained the services of d3 Medicine to provide strategic advice on the regulatory strategy to support the registration of moxidectin for onchocerciasis. The services of d3 Medicine have been retained through an innovative risk-share agreement for the benefit of both companies.

Read press release.

REFERENCES

Stay up to date

Follow our work by signing up for our newsletter

Thank you, your submission has been received.
Oops! Something went wrong while submitting the form.